Turning Point Therapeutics, Inc. (TPTX)
$75.49
Rating:
Recommendation:
-
| Symbol | TPTX |
|---|---|
| Price | $75.49 |
| Beta | -0.194 |
| Volume Avg. | - |
| Market Cap | - |
| Shares () | - |
| 52 Week Range | |
| 1y Target Est | - |
| DCF Unlevered | TPTX DCF -> | |
|---|---|---|
| DCF Levered | TPTX LDCF -> | |
| ROE | -23.45% | Sell |
| ROA | -23.42% | Sell |
| Operating Margin | - | |
| Debt / Equity | 0.62% | Neutral |
| P/E | -13.55 | Strong Sell |
| P/B | 4.73 | Strong Buy |
Latest TPTX news
About
Download (Excel)Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.